Treatment Advances in RASwt mCRC

 

ASCO 2022 Conference Coverage
T

Updates on the PARADIGM Trial: PAN + mFOLFOX6 vs. BEV + mFOLFOX6 as 1L in Pts With RAS WT mCRC

By ASCO 2022 Conference Coverage FEATURING Takayuki Yoshino
By ASCO 2022 Conference Coverage FEATURING Takayuki Yoshino
152 views
July 5, 2022
0 Comments
Login to view comments. Click here to Login
Treatment Advances in RASwt mCRC
05:18
Benjamin Weinberg

EGFR Targeted Therapy for mCRC: Differences Between Cetuximab and Pa…

05:34
ASCO GI 2023 Conference Coverage

ASCO GI 2023 Biomarker Study of The Phase III PARADIGM Trial: Negati…

Feat. K. Shitara
13:36
ASCO GI 2023 Conference Coverage

ASCO GI 2023 CTCs as Liquid Biopsies in Patients With mCRC vs. Other…

Feat. P. Kasi
17:44
Ibrahim Sahin

Impact of PARADIGM Data for RAS WT mCRC on Clinical Practice Treatme…

07:51
ASCO 2022 Conference Coverage

Updates on the PARADIGM Trial: PAN + mFOLFOX6 vs. BEV + mFOLFOX6 as …

Feat. T. Yoshino
18:29
Jesse Hirner

Dermatologic Toxicity of EGFR Inhibitors in mCRC

15:56
Van Morris

ASCO Updated Guidelines for the Treatment of Metastatic Colorectal C…

Feat. C. Eng
04:53
ecancer

Optimum Treatment Strategy Algorithm for mCRC

Feat. H. Lenz
10:08
ecancer

ESMO GI 2022 on CRC: Impact of BRAF-V600E Mutation on Tumor Microenv…

Feat. M. Salem
20:07
Timothy Price

Beyond 1L for mCRC - Best Practices and Practical Nuances

01:35
ESMO 2022 Conference Coverage

Lecture Summary - ESMO 2022: Beyond 1L for mCRC - Best Practices and…

Feat. T. Price
05:30
Julien Taieb

Updated ESMO Guidelines for mCRC